Scarica l'app Stockscreener
33.23
10.77%
3.23
Precedente Chiudi:
$30.00
Aprire:
$28.9906
Volume 24 ore:
8,851
Relative Volume:
0.22
Capitalizzazione di mercato:
$33.80M
Reddito:
Utile/perdita netta:
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
1 W Prestazione:
+0.00%
1M Prestazione:
+0.00%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$0.00
$0.00
Intervallo di 1 settimana:
$25.13
$33.71
Portata 52W:
$25.13
$33.71
IRulya Therapeutics Inc. Common Stock Stock (IRLA) Company Profile
Nome
IRulya Therapeutics Inc. Common Stock
Settore
Industria
Telefono
-
Indirizzo
-
Compare IRLA vs VRTX, MRNA, REGN, ARGX, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IRLA
IRulya Therapeutics Inc. Common Stock
|
33.23 | 33.80M | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
IRulya Therapeutics Inc. Common Stock Stock (IRLA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-10-09 | Iniziato | Raymond James | Outperform |
| 2026-09-24 | Iniziato | Rodman & Renshaw | Buy |
| 2026-09-22 | Aggiornamento | Citizens | Mkt Perform → Mkt Outperform |
| 2026-08-20 | Iniziato | Craig Hallum | Buy |
| 2026-07-29 | Iniziato | Oppenheimer | Outperform |
| 2026-06-24 | Iniziato | Leerink Partners | Outperform |
| 2026-06-23 | Iniziato | Cantor Fitzgerald | Overweight |
| 2026-01-30 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2025-08-05 | Iniziato | Citizens JMP | Mkt Outperform |
| 2025-03-24 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
IRulya Therapeutics Inc. Common Stock Borsa (IRLA) Ultime notizie
Quince Therapeutics relaunched as IRulya: Raymond James targeted QNCX stock at USD 72 - ad-hoc-news.de
IRulya Therapeutics Inc. (IRLA) Company Information - Simply Wall Street
IRulya Therapeutics (Nasdaq:IRLA)Stock Analysis - Simply Wall Street
Diluted net income available to common stockholders of IRulya Therapeutics Inc. – NASDAQ:IRLA - TradingView
Quince relaunches as IRulya, going all in on lung disease after Hail Mary merger - Fierce Pharma
Quince Therapeutics rebrands as IRulya, names new CEO - Investing.com
Quince Therapeutics Relaunches as IRulya Therapeutics with a Focus on the Clinical Development of LAM-001, Targeting a Key Pathway in Pulmonary Disease - GlobeNewswire
A $116 million cash balance on June 30, 2026, is expected to fund IRulya's operations through 2028. - Stock Titan
IRulya Therapeutics Inc. Common Stock Azioni (IRLA) Dati Finanziari
Non sono disponibili dati finanziari per IRulya Therapeutics Inc. Common Stock (IRLA). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
1.35%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):